

Hekun Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6217372/publications.pdf>

Version: 2024-02-01

20
papers

469
citations

687363

13
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of IL-6R α by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2022, 524, 161-171.	7.2	23
2	Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1 α -mediated EMT. <i>Molecular Carcinogenesis</i> , 2021, 60, 151-163.	2.7	13
3	Inhibition of Death-associated Protein Kinase 1 protects against Epileptic Seizures in mice. <i>International Journal of Biological Sciences</i> , 2021, 17, 2356-2366.	6.4	10
4	The Pin1-CaMKII-AMPA Receptor Axis Regulates Epileptic Susceptibility. <i>Cerebral Cortex</i> , 2021, 31, 3082-3095.	2.9	6
5	TCP1 regulates Wnt7b β -catenin pathway through P53 to influence the proliferation and migration of hepatocellular carcinoma cells. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 169.	17.1	16
6	Targeting PIN 1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. <i>Cancer Science</i> , 2019, 110, 2442-2455.	3.9	9
7	Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/ β -catenin oncogenic pathways. <i>Molecular Carcinogenesis</i> , 2019, 58, 1450-1464.	2.7	24
8	Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. <i>Cancer Letters</i> , 2019, 444, 82-93.	7.2	35
9	A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. <i>Journal of Controlled Release</i> , 2018, 269, 405-422.	9.9	49
10	GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma. <i>Molecular Medicine Reports</i> , 2018, 17, 4187-4194.	2.4	11
11	Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. <i>Journal of Hematology and Oncology</i> , 2018, 11, 73.	17.0	23
12	Lead Induces Genotoxicity via Oxidative Stress and Promoter Methylation of DNA Repair Genes in Human Lymphoblastoid TK6 Cells. <i>Medical Science Monitor</i> , 2018, 24, 4295-4304.	1.1	21
13	Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways. <i>Scientific Reports</i> , 2017, 7, 43639.	3.3	39
14	MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. <i>Scientific Reports</i> , 2017, 7, 45915.	3.3	43
15	Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 29771-29784.	1.8	30
16	Potential of the Antibody Against <i>cis</i> -Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. <i>JAMA Neurology</i> , 2016, 73, 1356.	9.0	64
17	Recognition of Cytosolic DNA Attenuates Glucose Metabolism and Induces AMPK Mediated Energy Stress Response. <i>International Journal of Biological Sciences</i> , 2015, 11, 587-594.	6.4	8
18	ADIPOQ +45T>G, +712A>G and +4545C>G variants are associated with dyslipidemia in Chinese pre-eclampsia women. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 206-210.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Association of $\hat{\sim}394C\>G$ and $\hat{\sim}420C\>G$ polymorphisms in the RETN gene with T2DM and CHD and a new potential SNP might be exist in exon 3 of RETN gene in Chinese. Molecular and Cellular Biochemistry, 2009, 330, 31-38.	3.1	14
20	APM1 gene variants $\hat{\sim}11377C/G$ and $4545G/C$ are associated respectively with obesity and with non-obesity in Chinese type 2 diabetes. Diabetes Research and Clinical Practice, 2009, 84, 205-210.	2.8	29